| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T68698 | ||||
| Target Name | Adenosylhomocysteinase | ||||
| Target Type | Discontinued |
||||
| Drug Potency against Target | ERITADENINE | Drug Info | IC50 = 30 nM | [530323] | |
| 5'-deoxy-5'-ureidoadenosine | Drug Info | IC50 = 7530 nM | [528908] | ||
| 5-methylenearisteromycin | Drug Info | IC50 = 15700 nM | [529335] | ||
| NORARISTEROMYCIN | Drug Info | IC50 = 3100 nM | [529398] | ||
| ARISTEROMYCIN | Drug Info | IC50 = 4850 nM | [529335] | ||
| FLUORO-NEPLANOCIN A | Drug Info | IC50 = 480 nM | [527252] | ||
| References | |||||
| Ref 530323 | Bioorg Med Chem. 2009 Sep 15;17(18):6707-14. Epub 2009 Jul 28.A new structural class of S-adenosylhomocysteine hydrolase inhibitors. | ||||
| Ref 528908 | Bioorg Med Chem Lett. 2007 Aug 15;17(16):4456-9. Epub 2007 Jun 8.Design, synthesis, and molecular modeling studies of 5'-deoxy-5'-ureidoadenosine: 5'-ureido group as multiple hydrogen bonding donor in the active site of S-adenosylhomocysteine hydrolase. | ||||
| Ref 529335 | Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. Epub 2008 Jan 30.Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. | ||||
| Ref 529398 | Bioorg Med Chem Lett. 2008 Apr 15;18(8):2615-8. Epub 2008 Mar 14.Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocysteine hydrolase. | ||||
| Ref 529335 | Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. Epub 2008 Jan 30.Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. | ||||
| Ref 527252 | Bioorg Med Chem Lett. 2004 Nov 15;14(22):5641-4.Synthesis of 5'-substituted fluoro-neplanocin A analogues: importance of a hydrogen bonding donor at 5'-position for the inhibitory activity of S-adenosylhomocysteine hydrolase. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.